CPhI Online

- Market News

Alfasigma increases liquid injectable vial capacity with new sterile department at Alanno plant

27 Oct 2020

Italian pharma company Alfasigma has increased its capacity for production of liquid injectable vials with the 2020 launch of a new sterile department of excellence at its Alanno manufacturing plant.

The new department boasts a cutting-edge, high-speed and fully automatic IMA filling line with a productivity of 18,000 pcs/h, capable of filling aseptic liquid vials.

The high containment segregated line can handle small filling volumes up to 100 ml, allows for management of the track and trace on the primary packaging, and performs continuous and 100% weight checks.

Fully integrated sterilization systems (ovens, autoclaves, passboxes) ensure the safety of the aseptic area in the line, according to top quality standard requirements.

All equipment is connected to a validated computer system in order to guarantee the complete traceability and integrity of the data.

Given its advanced technical characteristics, the new line is particularly suitable to supporting production processes requiring outstanding reliability for the manufacturing of high-value products such as biotechnology compounds, biosimilars and vaccines.

The expansion has increased Alfasigma’s overall annual production capacity of to 250 million vials, which is welcome news given increased vial demand related to the current COVID-19 pandemic situation.

The new department is part of an overall 450 sqm expansion at Alanno, which also includes a new department completely dedicated to the production of pre-filled syringes, cartridges and ready-to-use vials.

Alfasigma is a privately-owned, Italy-based integrated multinational pharmaceutical company with revenues in excess of €1 billion, five manufacturing plants, R&D facilities, and 3,000 employees globally. Outside of its core Italian market, Alfasigma has 16 subsidiaries in Europe, Asia, North and Central America and Africa, and is present in more than 90 countries.

The Alanno plant processes rifaximin, a molecule for the treatment of gastrointestinal disorders, which holds the record for US sales of an Italian-owned drug (over €1.5 billion euros, according to IQVIA).

Click here to download an infographic on Alfasigma's two new sterile departments at Alanno

Click here to download an inforgraphic on Alfasigma's products and services


Related Content